CClinicalTrials.gg
Sign In
RecruitingNCT07341984Train ALSUpdated Jan 15, 2026

A Physiotherapy Intervention Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

An interventional study of Individualized Physiotherapy in Amyotrophic Lateral Sclerosis, sponsored by Charlotte Vogt. Recruiting at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Charlotte Vogt · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Dec 2025; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Sex
All
01

Study summary

This study investigates whether an individualized physiotherapy program, tailored to each patient's specific motor deficits, can better support physical function compared with usual care physiotherapy in people with ALS.

The individualized program is guided by diagnostic assessments using a robotic leg press system, which helps identify strengths and weaknesses in muscle function and movement control.

Participants will receive either individualized physiotherapy or standard physiotherapy and will be followed for 12 months. The aim of the study is to improve physiotherapy strategies for people with ALS in a safe and patient-centered manner.

02

Conditions studied

  • Amyotrophic Lateral Sclerosis
03

In context

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 283 are open to participants now.

This study's planned enrollment of 38 is close to the median of 36 across 667 interventional studies indexed under Amyotrophic Lateral Sclerosis.

Browse Amyotrophic Lateral Sclerosis studies →

Lead sponsor

This is the only study on the registry with Charlotte Vogt as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • diagnosis of clinically probable, probable laboratory-supported, or definite ALS (revised El Escorial criteria) or upper motor neuron only (OPM classification [onset, propagation, motoneuron involvement])
  • age ≥18 years; ability to understand study information and provide written informed consent
  • Willingness and ability to perform individualized exercise according to the study protocol (approximately three to five sessions of 30 minutes per week) for the duration of the intervention period
  • Individuals of all sexes and gender identities are eligible for inclusion

Exclusion criteria

Exclusion Criteria:

  • pregnancy, tracheostomy, continuous assisted ventilation, or other significant non-ALS pulmonary disease
  • other neurodegenerative or neuromuscular conditions that may confound assessments
  • concomitant life-threatening disease or impairment interfering with functional assessment
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Individualized Physiotherapy Group

    This group receives an individualized physiotherapy program tailored to patient-specific functional deficits. Two thrids of participants are allocated to the intervention group.

    Other: Individualized Physiotherapy

  • Active comparator
    Usual Care Physiotherapy Group

    This group continues to receive usual care physiotherapy in accordance with standard clinical practice. One third of participants are allocated to the control group.

    Other: Individualized Physiotherapy

Interventions

  • OtherIndividualized Physiotherapy

    see above

06

What researchers measure

Primary outcomes

  1. Climbing stairs (ALSFRS-R [amyotrophic lateral sclerosis functional rating scale - revised] - item 9: score range 0 to 4 with 4 indicating normal function)

    funcitonal

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07341984
Lead sponsor
Charlotte Vogt
Responsible party
Charlotte Vogt (Sponsor-Investigator, Cantonal Hospital of St. Gallen) — Sponsor-investigator
First posted
Jan 15, 2026
Start date
Dec 16, 2025
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 15, 2028 (estimated)
Last update
Jan 15, 2026

Study contacts

Charlotte Vogt
Contact
charlotte.vogt@h-och.ch
0041714943581
Oleksandra Hoptar
Contact
oleksandra.hoptart@h-och.ch
0041714943581

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Amyotrophic Lateral Sclerosis→

Start the discussion